Boehringer Ingelheim will conduct biophysical and structural studies, including cryo-electron microscopy (cryoEM), on Boehringer pipeline targets enabled by the Salipro®-technology to identify ...

They compared an original set of prints taken in Puerto Rico in 1986, the year before Milla-Valdes fled incarceration, with another set collected by authorities in South Florida's Monroe County ...

(Image Credits: Pixabay) Boehringer Ingelheim’s blockbuster diabetes drug, Empagliflozin, is now off-patent in India, paving the way for domestic drugmakers to launch generic versions.

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia from Sosei Heptares, which it says could have broad activity against the symptoms of ...

I think it’s called Puerto Rico,” he said onstage. “I welcome migrants to the United States with open arms, and by open arms, I mean like this,” he said, with hand gestures signaling “no ...

Credit: Tapati Rinchumrus/Shutterstock. Boehringer Ingelheim and Sweden-based Salipro Biotech have entered a research and licence agreement to expedite the development of several drug targets. The ...

Boehringer Ingelheim/Eli Lilly) and dapagliflozin (Farxiga; AstraZeneca). Amazingly, said Perera, medical therapy has evolved further since the publication of the REVIVED-BCIS2 trial results 30 months ...

Oakville, ON, March 13, 2025 (GLOBE NEWSWIRE) — HealthPRO Canada, Canada’s national group contracting provider for healthcare, is proud to announce it has been named as one of the 2025 Best ...

VANCOUVER, British Columbia, March 13, 2025 (GLOBE NEWSWIRE) — Orezone Gold Corporation (TSX: ORE, OTCQX: ORZCF) (the “Company” or “Orezone”) is pleased to announce that it has completed ...

INGELHEIM, Germany and PLEASANTON, Calif., March 11, 2025 /PRNewswire/ -- Today, Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) have announced the launch of Boehringer’s One Medicine Platform, ...

Cognizant, as the prime system integrator, began the Boehringer Ingelheim project by codeveloping a program roadmap, agile methodology, and implementation workflow. The overall scope of the project ...